--- title: "Pre-market hot trades in US stocks: Hims & Hers Health pre-market down 3.05%; Astrazeneca pre-market down 3.04%" description: "Hims & Hers Health pre-market down 3.05%; Astrazeneca pre-market down 3.04%; Helius Medical Tech pre-market up 170.24%; Check Cap pre-market up 148.02%; InnSuites Hospitality Trust pre-market up 118.5" type: "news" locale: "en" url: "https://longbridge.com/en/news/257325725.md" published_at: "2025-09-15T09:08:17.000Z" --- # Pre-market hot trades in US stocks: Hims & Hers Health pre-market down 3.05%; Astrazeneca pre-market down 3.04% > Hims & Hers Health pre-market down 3.05%; Astrazeneca pre-market down 3.04%; Helius Medical Tech pre-market up 170.24%; Check Cap pre-market up 148.02%; InnSuites Hospitality Trust pre-market up 118.50% **Popular Pre-Market Trades in U.S. Stocks** Hims & Hers Health is down 3.05% in pre-market trading. Based on recent key news: 1. On September 13, FDA Director Robert Califf pointed out that Hims & Hers' advertisements during the Super Bowl violated federal law by failing to fairly present the risks and benefits of the drugs, damaging the company's brand image. 2. On September 12, Bank of America Securities maintained a sell rating on Hims & Hers, reflecting a cautious market outlook on the company's prospects. 3. On September 13, the FDA announced it would issue a large number of warning letters reminding pharmaceutical companies to comply with advertising rules, heightening market concerns about regulatory risks for Hims & Hers. The health industry is facing regulatory pressure, leading to increased market volatility. AstraZeneca is down 3.04% in pre-market trading. According to recent key news: 1. On September 13, AstraZeneca announced the suspension of its £200 million expansion plan in Cambridge, UK, leading to a drop in stock prices. The plan was expected to create 1,000 jobs but was shelved due to reduced government support in the UK. 2. On September 13, AstraZeneca received a notice from the National Pharmaceutical Pricing Authority in India for allegedly overcharging for drugs, involving an amount of ₹605 million, increasing the regulatory pressure the company faces. 3. On September 15, Swedish bank downgraded AstraZeneca's rating from buy to hold, reflecting market concerns about the company's future growth. The UK pharmaceutical industry is facing investment uncertainty. **Top Gainers in Pre-Market U.S. Stocks** Check Cap is up 148.02% in pre-market trading. Based on recent key news: 1. On September 15, Israeli company Check-Cap announced a merger agreement with MBody AI, driving the stock price up approximately 165% in pre-market trading. The merger will allow Check-Cap to enter a high-growth industry while retaining its patents and proprietary medical device assets. 2. On September 13, Check-Cap shareholders need to approve the merger agreement; if approved, the previous merger agreement with Apollo Technology Capital will be terminated. Following the announcement, Check-Cap's stock price rose to $2.25 in after-hours trading. 3. On September 12, Check-Cap signed a final merger agreement with MBody AI, and the merged company will be renamed "MBODY AI LTD." Existing MBody AI shareholders will hold 90% of the merged company, while Check-Cap shareholders will hold 10%. Industry trends and macro dynamics need to be monitored. InnSuites Hospitality Trust is up 118.50% in pre-market trading. Based on recent key news: 1. On September 12, InnSuites Hospitality Trust announced that its hotel revenue for the first half of fiscal year 2026 exceeded $4 million again, with total revenue of approximately $4,004,635. This strong financial performance drove a significant increase in stock prices. Source: GLOBE NEWSWIRE. 2. On September 12, InnSuites Hospitality Trust announced plans to leverage its real estate equity by selling hotel assets over the next 36 months and to explore diversification opportunities, including a potential reverse merger. These strategic initiatives have enhanced market confidence in its future growth. Source: SEC Filing. 3. On September 12, InnSuites Hospitality Trust continued to advance its management of IBC Hotels and its investment in UniGen Power Inc., expecting to achieve substantial profits. This optimistic outlook further boosted investor sentiment. Source: SEC Filing. Strong hotel performance and strategic diversification ### Related Stocks - [HIMS.US - Hims & Hers Health](https://longbridge.com/en/quote/HIMS.US.md) - [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | AstraZeneca PLC $AZN Shares Sold by Ontario Teachers Pension Plan Board | Ontario Teachers Pension Plan Board reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 41% in Q3, now holding 817,880 | [Link](https://longbridge.com/en/news/276339476.md) | | AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients | AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients | [Link](https://longbridge.com/en/news/276444179.md) | | Daiichi Sankyo and AstraZeneca get EU validation for Enhertu use | Daiichi Sankyo and AstraZeneca have received validation from the European Medicines Agency for their application to exte | [Link](https://longbridge.com/en/news/276408087.md) | | Is Hims & Hers Health Inc Gaining or Losing Market Support? | Hims & Hers Health Inc (NYSE:HIMS) has seen a 6.24% increase in short interest, with 76.76 million shares sold short, re | [Link](https://longbridge.com/en/news/276248796.md) | | Earnings Outlook For Hims & Hers Health | Hims & Hers Health (NYSE:HIMS) is set to announce its quarterly earnings on February 23, 2026, with analysts predicting | [Link](https://longbridge.com/en/news/276467301.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.